In this Q&A, Charles Lynde, MD, highlighted upadacitinib's impact on severe alopecia areata in new phase 3 data addressing the hair loss condition.
Charles Lynde, MD
Advertisement
Charles Lynde, MD, is an associate professor in the Department of Medicine at the University of Toronto. He is the also Chief Medical Director of Lynde Institute for Dermatology and Lynderm Research.
Articles by Charles Lynde, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
Pamufetinib Fails to Slow FVC Decline in Progressive Fibrosing ILD
2
Brensocatib Patient Selection Evolves 1 Year After FDA Approval
3
FDA Accepts NDA for Ralinepag in Pulmonary Arterial Hypertension
4
Allergists Debate: Which Nonsteroidal to Use for Atopic Dermatitis?
5